Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEONIPIGA: Nivolumab and Ipilimumab in Localized MSI/dMMR Oeso-gastric Cancer
NCT04006262Phase 2Active, not recruiting
- Sponsor
- GERCOR
- Start
- Oct 2019
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by GERCOR. Primary endpoint: Complete Pathological Response Rate up to 30 months. Started Oct 2019; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04006262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04006262.